- Home
- EXLS vs HALO Comparison
EXLS vs HALO Comparison
Compare EXLS & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EXLS | HALO |
|---|---|---|
| Founded | 1999 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3B | 8.1B |
| IPO Year | 2004 | 2001 |
Fundamental Metrics
Financial Performance| Metric | EXLS | HALO |
|---|---|---|
| Price | $27.06 | $78.55 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 11 |
| Target Price | $46.80 | ★ $78.64 |
| AVG Volume (30 Days) | ★ 2.6M | 1.6M |
| Earning Date | 04-28-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 27.27 | N/A |
| EPS | 0.43 | ★ 1.22 |
| Revenue | N/A | ★ $151,862,000.00 |
| Revenue This Year | $12.61 | $28.24 |
| Revenue Next Year | $10.55 | $12.56 |
| P/E Ratio | ★ $62.85 | $65.16 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $24.85 | $53.65 |
| 52 Week High | $47.08 | $82.22 |
Technical Indicators
Market Signals| Indicator | EXLS | HALO |
|---|---|---|
| Relative Strength Index (RSI) | 45.90 | 72.47 |
| Support Level | $26.88 | $67.12 |
| Resistance Level | $32.82 | $79.50 |
| Average True Range (ATR) | 1.02 | 2.42 |
| MACD | 0.01 | 0.89 |
| Stochastic Oscillator | 50.00 | 99.52 |
Price Performance
Historical ComparisonAbout EXLS ExlService Holdings Inc.
ExlService Holdings Inc. is a data analytics and digital operations company that provides data and AI-led solutions and technology-enabled services to clients across industries. The company has four reportable segments. The Insurance segment provides services such as claims management, underwriting support, and analytics solutions. The Healthcare and Life Sciences segment offers data-driven solutions and services to healthcare payers, providers, and life sciences organizations. The Banking, Capital Markets and Diversified Industries segment delivers solutions across financial services and other industries. The International Growth Markets segment focuses on providing data, AI, and digital operations services to clients outside North America.
About HALO Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.